• Je něco špatně v tomto záznamu ?

Cardiotoxicity of β-mimetic catecholamines during ontogenetic development - possible risks of antenatal therapy

B. Ostadal, A. Parizek, I. Ostadalova, F. Kolar,

. 2018 ; 96 (7) : 639-646.

Jazyk angličtina Země Kanada

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc19000817

Catecholamines are involved in the regulation of a wide variety of vital functions. The β-adrenergic receptor (β-AR) - adenylyl cyclase system has been identified early in embryogenesis before the heart has received adrenergic innervation. The structure of β-receptors in the immature myocardium is similar to that in adults; there are, however, significant quantitative developmental changes in the inotropic and chronotropic responsiveness. Information on the toxic effect of the β-AR agonists in the immature heart is surprisingly scarce, even though these agents are used in clinical practice both during pregnancy and in early postnatal development. Large doses of β-AR agonists induce malformations of the cardiovascular system; the type of change depends upon the time at which the β-AR agonist was administered during embryogenesis. During postnatal ontogeny, the cardiotoxicity of β-AR agonists increased from birth to adulthood. It seems likely that despite interspecies differences, developmental changes in the cardiac sensitivity to β-AR agonists may exist in all mammals, depending on the degree of maturation of the system involved in β-adrenergic signaling. All the existing data draw attention to the possible harmful consequences of the clinical use of β-AR agonists during early phases of cardiac development. Late effects of the early disturbances of the cardiac muscle cannot be excluded.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19000817
003      
CZ-PrNML
005      
20190115100629.0
007      
ta
008      
190107s2018 xxc f 000 0|eng||
009      
AR
024    7_
$a 10.1139/cjpp-2017-0774 $2 doi
035    __
$a (PubMed)29633627
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxc
100    1_
$a Ostadal, B $u a Institute of Physiology, Czech Academy of Sciences, Videnska 1083, 14220 Prague 4, Czech Republic.
245    10
$a Cardiotoxicity of β-mimetic catecholamines during ontogenetic development - possible risks of antenatal therapy / $c B. Ostadal, A. Parizek, I. Ostadalova, F. Kolar,
520    9_
$a Catecholamines are involved in the regulation of a wide variety of vital functions. The β-adrenergic receptor (β-AR) - adenylyl cyclase system has been identified early in embryogenesis before the heart has received adrenergic innervation. The structure of β-receptors in the immature myocardium is similar to that in adults; there are, however, significant quantitative developmental changes in the inotropic and chronotropic responsiveness. Information on the toxic effect of the β-AR agonists in the immature heart is surprisingly scarce, even though these agents are used in clinical practice both during pregnancy and in early postnatal development. Large doses of β-AR agonists induce malformations of the cardiovascular system; the type of change depends upon the time at which the β-AR agonist was administered during embryogenesis. During postnatal ontogeny, the cardiotoxicity of β-AR agonists increased from birth to adulthood. It seems likely that despite interspecies differences, developmental changes in the cardiac sensitivity to β-AR agonists may exist in all mammals, depending on the degree of maturation of the system involved in β-adrenergic signaling. All the existing data draw attention to the possible harmful consequences of the clinical use of β-AR agonists during early phases of cardiac development. Late effects of the early disturbances of the cardiac muscle cannot be excluded.
650    _2
$a adenylátcyklasy $x metabolismus $7 D000262
650    _2
$a agonisté adrenergních beta-receptorů $x škodlivé účinky $7 D000318
650    _2
$a zvířata $7 D000818
650    _2
$a kardiotoxicita $x etiologie $7 D066126
650    _2
$a katecholaminy $x škodlivé účinky $7 D002395
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a srdce $x účinky léků $x embryologie $7 D006321
650    _2
$a lidé $7 D006801
650    _2
$a těhotenství $7 D011247
650    _2
$a beta-adrenergní receptory $x metabolismus $7 D011943
650    _2
$a signální transdukce $x účinky léků $7 D015398
650    _2
$a tokolytika $x škodlivé účinky $7 D015149
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Parizek, A $u b Department of Obstetrics and Gynecology, 1st Faculty of Medicine, Charles University and General Faculty Hospital, Prague, Czech Republic.
700    1_
$a Ostadalova, I $u a Institute of Physiology, Czech Academy of Sciences, Videnska 1083, 14220 Prague 4, Czech Republic.
700    1_
$a Kolar, F $u a Institute of Physiology, Czech Academy of Sciences, Videnska 1083, 14220 Prague 4, Czech Republic.
773    0_
$w MED00001020 $t Canadian journal of physiology and pharmacology $x 1205-7541 $g Roč. 96, č. 7 (2018), s. 639-646
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29633627 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20190115100840 $b ABA008
999    __
$a ok $b bmc $g 1364813 $s 1038940
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 96 $c 7 $d 639-646 $i 1205-7541 $m Canadian journal of physiology and pharmacology $n Can J Physiol Pharmacol $x MED00001020
LZP    __
$a Pubmed-20190107

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...